'Important deals' on the horizon for Gilead, new CEO says


Gilead Sciences has said that it would only use its flush cash reserves for M&A if the right deal came along. Now, with a slowdown in the company’s hep C franchise and a new leader at the helm, it's getting more aggressive about its search.

“It’s time for us to go out and do important deals,” CEO John Milligan told Bloomberg. “We need some other assets that can bolster our pipeline.”

A new cancer product would be key, Milligan said, as Gilead looks to expand in cancer markets as well as liver diseases and inflammatory disorders. The company will keep its scope wide and consider products for many types of cancer, he added. But each deal must answer the question: “What is going to be the cutting-edge technology five years from now, and would I be part of that?” Milligan said, as quoted by Bloomberg.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

With $21 billion in cash and equivalents in its coffers, Gilead has some fuel for dealmaking. Milligan is staying quiet about potential targets. But Leerink Partners analyst Geoffrey Porges thinks that the CEO would need to find an asset that would contribute $5 billion to $10 billion in the next 5 to 10 years in order to “move the needle.”

Besides looking for cancer assets, the Foster City, CA-based company is also investing in therapies for nonalcoholic steatohepatitis (NAS). Gilead recently shelled out $400 million upfront for an early-stage drug for NASH, the first deal under new CEO Milligan.

Gilead last quarter reported slumping sales of its hep C superstars Sovaldi and Harvoni as rival products from AbbVie ($ABBV) and Merck ($MRK) gain momentum. Even though some analysts expected the drop, “the magnitude of the decline is stunning,” SVP and portfolio manager of F.L. Putnam Investment Management Steven Violin told Bloomberg at the time.

New deals could help turn the tide. Milligan, who took the reins from former CEO John Martin in March, has said recently that Gilead would “aggressively” pursue deals and be “opportunistic in M&A.”

The company hasn’t done a big deal since it snatched up Pharmasset in 2011 for $11 billion to get its hands on its hep C powerhouse Sovaldi. But some analysts are betting that new leadership a la Milligan will help the company achieve its renewed M&A ambitions. The CEO might not hit the target “every time, but over time this a guy you want to bet on,” Evercore ISI analyst Mark Schoenebaum told Bloomberg.

- read the Bloomberg story

Related Articles:
Gilead Sciences' John Martin stepping out of CEO role after two decades, is replaced by John Milligan
Gilead's hep C juggernaut continues in Q4, even as U.S. sales fall
Gilead faces Q3 slowdown for hep C superstars
Gilead ready to take the cash from hep C superstars and buy something
Merck wins first round in $3B-plus hep C royalty fight with Gilead


Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.